SCHEMBL3963801

SCHEMBL3963801

Cc1ccc(O)c(S(=O)(=O)Nc2cc(OC3CCNCC3)c3occc3c2)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.82
SGK1 O00141 6/20 0.40
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 3/20 0.35
NMT1 P30419 1/20 0.35
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35
LMNA P02545 2/20 0.35
PKM P14618 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
SYK P43405 1/20 0.34
HPGD P15428 1/20 0.33
ALPL P05186 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3958865 0.90 HTR6 (1.00) HTR6SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL13361991 0.89 HTR6 (0.79) HTR6SGK1PDE4APDE4BPDE4C
SCHEMBL13703580 0.83 HTR6 (0.63) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL3960019 0.80 HTR6 (0.81) HTR6SGK1SMN1; SMN2MEN1KMT2A
SCHEMBL3956245 0.80 HTR6 (0.78) HTR6SMN1; SMN2MEN1KMT2AALPL
SCHEMBL3958890 0.79 HTR6 (0.64) HTR6SYK
SCHEMBL3960413 0.78 HTR6 (0.71) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL2966777 0.77 HTR6 (0.72) HTR6SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL3324083 0.77 HTR6 (0.76) HTR6SGK1SMN1; SMN2MEN1KMT2A
SCHEMBL3324077 0.77 HTR6 (0.76) HTR6SGK1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582767-B2 Substituted sulphonamide compound and uses thereof BIOVITRUM AB (PUBL.) (SE) 2009-09-01 US disclosed
EP-1896460-B1 BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS BIOVITRUM AB PUBL (SE) 2009-07-22 EP disclosed
EP-1896460-A1 BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS Biovitrum AB (publ) (SE) 2008-03-12 EP disclosed
US-20060293361-A1 N-[7-(4-piperidinyl)oxy-1-benzofuran-5-yl]-5-hydroxymethyl-2-methoxybenzenesulfonamide; the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, CNS disorders, to achieve reduction of body weight and/or body weight gain PROXIMAGEN NEUROSCIENCE PLC (GB) 2006-12-28 US disclosed
WO-2006134150-A1 BENZOFURANYL DERIVATIVES AS 5-HT6-RECEPTOR INHIBITORS BIOVITRUM AB (PUBL) (SE) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293361-A1 N-[7-(4-piperidinyl)oxy-1-benzofuran-5-yl]-5-hydroxymethyl-2-methoxybenzenesulfonamide; the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, CNS disorders, to achieve reduction of body weight and/or body weight gain GPR119, CNR2, SULT1E1 HTR6 598/4885SGK1 4799/4885PDE4A 2128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.